Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nuvisertib - Sumitomo Pharma America

Next Previous
Drug Profile

Nuvisertib - Sumitomo Pharma America

Alternative Names: SGI-9481; TP-3654

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tolero Pharmaceuticals
  • Developer Sumitomo Pharma America
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Cyclohexanes; Imidazoles; Pyridazines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelofibrosis
  • Preclinical Triple negative breast cancer
  • No development reported Solid tumours
  • Discontinued Inflammation

Most Recent Events

  • 27 Jun 2025 3900484: Intro, KDM, Product tab, Dev tab, Clinical sec and HE updated
  • 12 Jun 2025 Nuvisertib - Sumitomo Pharma America receives Fast Track designation for Myelofibrosis [PO] (Monotherapy, Second-line therapy or greater) in USA
  • 12 Jun 2025 Updated efficacy and adverse event data from a phase-I/II trial in Myelofibrosis released by Sumitomo Pharma America

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top